- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Enhertu (trastuzumab deruxtecan) as monotherapy for unresectable or metastatic HER2-positive breast cancer patients who have received one or more prior anti-HER2-based regimens.
- Enhertu is being jointly developed and commercialized by AstraZeneca Plc AZN and Daiichi Sankyo DSNKY.
- Also Read: AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50%.
- The positive opinion is based on results from the DESTINY-Breast03 Phase 3 trial, in which Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine.
- CHMP also backed Lynparza (olaparib) as monotherapy or combined with endocrine therapy as adjuvant treatment of HER2-negative high-risk early breast cancer with germline BRCA1/2 mutations (gBRCAm) in previously treated patients with neoadjuvant or adjuvant chemotherapy.
- Lynparza demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival, reducing the risk of invasive breast cancer recurrences, new cancers, or death by 42% versus placebo.
- Lynparza is jointly developed and commercialized by AstraZeneca and Merck & Co Inc MRK.
- Price Action: AZN shares are down 0.48% at $66.58 during the premarket session on the last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.